U.SK, dermatology arm of Brazilian NC Group, and Sonoma Pharmaceuticals Enter into License Agreement for Exclusive Rights to ...
June 05 2018 - 7:05AM
U.SK Dermatology, the dermatology arm of NC Group, which besides
other businesses is the largest pharmaceutical organization in
Brazil both in units sold and revenues, and Sonoma Pharmaceuticals,
Inc. (Nasdaq: SNOA), a specialty pharmaceutical company that
develops and markets unique and effective dermatological
solutions, announced today they have entered into a license and
supply partnering agreement for the exclusive distribution of
multiple Sonoma dermatology products into Brazil, including*:
- GramaDerm™ Hydrogel –
for acne.
- GramaDerm™ Liquid – for
acne.
- Celacyn™ – as a scar treatment.
- Pediacyn™ Spray – for atopic
dermatitis treatment.
- Pediacyn™ Gel – for atopic dermatitis
treatment.
- Lasercyn™ Spray
– for skin cleansing following cosmetic
procedures.
- Lasercyn™ Hydrogel – for skin cleansing
following cosmetic procedures.
“Having access to Sonoma’s HOCl-based technology provides us
with the first-ever hypochlorous acid-based products in the
Brazilian dermatology market. We believe the integration of
these products into U.SK Dermatology’s portfolio of strong brands
and supporting Brazilian dermatologist’s treatment protocols will
improve patient outcomes relative to various afflictions,” said
Jailson Bispo, U.SK CEO.
“We are thrilled to partner with U.SK Dermatology, who shares
our vision of providing alternate dermatology solutions to topical
antibiotics and steroids. U.SK has demonstrated they can
successfully compete and win in the Brazilian dermatology market
against multi-national pharmaceutical companies,” said Jim Schutz,
Sonoma’s CEO.
NC Group, with over $3 billion in annual revenues and strong
go-to-market capabilities, will market and sell Sonoma’s
hypochlorous acid-based products to dermatologists and pharmacies
throughout Brazil under its dermatology arm U.SK Dermatology.
Sonoma and U.SK have been working closely on a launch plan that
leverages Sonoma’s U.S. dermatology success in combination with
U.SK and NC Group’s history of successful execution in the
Brazilian market. First products are expected to hit the
market in August 2018.
Conference CallA conference call to discuss the
Brazilian licensing agreement is scheduled for 1:30 p.m. PDT on
June 5, 2018. Individuals interested in participating in the
conference call may do so by dialing 877-303-7607 for domestic
callers or 973-638-3203 for international callers. Those
interested in listening to the conference call live via the
internet may do so at
https://edge.media-server.com/m6/p/ckmsg25z.
A telephone replay will be available for seven days following
the conclusion of the call by dialing 855-859-2056 for domestic
callers, or 404-537-3406 for international callers, and entering
conference code 3197219. A webcast replay will be available on the
site at http://ir.sonomapharma.com/events.cfm for one year
following the call.
About the Brazilian Dermatology MarketAccording
to a research report from IQVIA, the Brazilian dermatology market
is $1.5 billion in sales annually and has grown at an annual rate
of 10% over the past five years.
About NC GroupNC Group is a
Brazilian holding company with over 50 years of successful
operations across several economic sectors, such as
pharmaceuticals, energy, media and real estate. With
headquarters in the city of Hortolandia in São Paulo state, NC
Group employs over seven thousand employees and has more than ten
companies under its umbrella. According to IQVIA, its
pharmaceutical arm has been the largest pharma organization in
Brazil for the last twelve years and third in Latin America
operating in the segment of medical prescription, generics, branded
drugs, OTC and hospital. NC Group has a presence in the North
American market through Brace Pharma, a venture capital focused on
break-through innovation. NC Group also consistently invests in
incremental innovation and is one of Bionovis' shareholders of
biotechnology medicines - considered the future of the
pharmaceutical industry.
About Sonoma Pharmaceuticals, Inc.Sonoma is a
specialty pharmaceutical company that develops and markets unique
and effective solutions for the treatment of dermatological
conditions and advanced tissue care. The company’s products, sold
throughout the United States and internationally, have improved
outcomes for more than five million patients globally by
reducing infections, itch, pain, scarring and harmful
inflammatory responses. The company's headquarters are in Petaluma,
California, with manufacturing operations in the United States
and Latin America. European marketing and sales are
headquartered in Roermond, Netherlands. More information can be
found at www.sonomapharma.com.
Forward-Looking StatementsExcept for historical
information herein, matters set forth in this press release
are forward-looking within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995,
including statements about the commercial and technology progress
and future financial performance of Sonoma Pharmaceuticals,
Inc. and its subsidiaries (the “Company”). These forward-looking
statements are identified by the use of words such as “expect,”
“launch,” and “believe,” among others. Forward-looking statements
in this press release are subject to certain risks and
uncertainties inherent in the Company’s business that could cause
actual results to vary, including such risks
that regulatory clinical and guideline developments may
change, scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances
or approvals, clinical results may not be replicated in actual
patient settings, protection offered by the
Company’s patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available
market for the Company’s products will not be as
large as expected, the Company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to fund further development and clinical studies,
as well as uncertainties relative to varying product formulations
and a multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the Company’s filings with the Securities and
Exchange Commission. The Company disclaims any obligation to update
these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals®, Gramaderm™, and Celacyn™ are trademarks
or registered trademarks of Sonoma Pharmaceuticals, Inc. All other
trademarks and service marks are the property of their respective
owners.
*Note – Trademarks listed are those already owned by Sonoma in
various geographies.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
Bob MillerCFO(925) 787-6218
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Sep 2023 to Sep 2024